Heikki Tuomas Joensuu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7315118/publications.pdf

Version: 2024-02-01

178	19,159	41627	13635
papers	citations	51 h-index	134 g-index

181	181	181	18030
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Accelerator-based boron neutron capture therapy facility at the Helsinki University Hospital. Acta OncolÃ³gica, 2022, 61, 269-273.	0.8	26
2	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	3.2	18
3	Long-Term Survival Outcomes of Patients with Small (â‰¤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study. Breast Care, 2022, 17, 279-287.	0.8	1
4	Fibrinogenâ€like protein 2 in gastrointestinal stromal tumour. Journal of Cellular and Molecular Medicine, 2022, 26, 1083-1094.	1.6	3
5	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	2.3	33
6	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. Journal of Clinical Oncology, 2022, , JCO2102054.	0.8	14
7	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. British Journal of Cancer, 2022, 126, 1401-1409.	2.9	11
8	Effects of capecitabine as part of neo-/adjuvant chemotherapy â€“ A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer, 2022, 166, 185-201.	1.3	13
9	Rapid Absorption of Naloxone from Eye Drops. Pharmaceuticals, 2022, 15, 532.	1.7	0
10	Comparison of Photon Isoeffective Dose Models Based on In Vitro and In Vivo Radiobiological Experiments for Head and Neck Cancer Treated with BNCT. Radiation Research, 2022, 198, .	0.7	1
11	MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. IScience, 2022, 25, 104459.	1.9	3
12	Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study.. Journal of Clinical Oncology, 2022, 40, 11535-11535.	0.8	1
13	Extracellular vesicles as modifiers of antibodyâ€drug conjugate efficacy. Journal of Extracellular Vesicles, 2021, 10, e12070.	5.5	17
14	ANO1 Expression Orchestrates p27Kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 1170.	1.7	7
15	CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. Cancer Research, 2021, 81, 4319-4331.	0.4	26
16	Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer. Cancers, 2021, 13, 3626.	1.7	9
17	Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer. Cancers, 2021, 13, 3892.	1.7	11
18	Compressive stress-mediated p38 activation required for ERÎ±â€‰+â€‰phenotype in breast cancer. Nature Communications, 2021, 12, 6967.	5.8	22

#	Article	IF	Citations
19	Reactive stroma and trastuzumab resistance in HER2â€positive early breast cancer. International Journal of Cancer, 2020, 147, 266-276.	2.3	13
20	ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Letters, 2020, 473, 156-163.	3.2	39
21	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors. JAMA Oncology, 2020, 6, 1241.	3.4	111
22	Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Acta OncolÃ³gica, 2020, 59, 1064-1071.	0.8	2
23	Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer. Nutrients, 2020, 12, 407.	1.7	5
24	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. Clinical Cancer Research, 2020, 26, 2603-2614.	3.2	20
25	Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.. Journal of Clinical Oncology, 2020, 38, 11503-11503.	0.8	3
26	Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.. Journal of Clinical Oncology, 2020, 38, 11533-11533.	0.8	0
27	Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.. Journal of Clinical Oncology, 2020, 38, 510-510.	0.8	2
28	Challenges of international oncology trial collaborationâ€"a call to action. British Journal of Cancer, 2019, 121, 515-521.	2.9	17
29	A Novel Anti-HER2 Antibodyâ€"Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Molecular Cancer Therapeutics, 2019, 18, 1721-1730.	1.9	47
30	SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nature Communications, 2019, 10, 2340.	5.8	49
31	Breast cancer outcome prediction with tumour tissue images and machine learning. Breast Cancer Research and Treatment, 2019, 177, 41-52.	1.1	80
32	Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival. Radiotherapy and Oncology, 2019, 137, 153-158.	0.3	43
33	Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. EMBO Molecular Medicine, 2019, 11, .	3.3	38
34	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
35	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nature Communications, 2019, 10, 620.	5.8	60
36	Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancerâ€"Reply. JAMA Oncology, 2019, 5, 118.	3.4	1

#	Article	IF	Citations
37	Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.	3.2	14
38	Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1092-1101.	3.3	13
39	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2019, 37, 11023-11023.	0.8	9
40	Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).. Journal of Clinical Oncology, 2019, 37, 3142-3142.	0.8	7
41	Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. Journal of Cellular and Molecular Medicine, 2018, 22, 2220-2230.	1.6	13
42	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research, 2018, 20, 15.	2.2	71
43	Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study. British Journal of Cancer, 2018, 118, 1529-1535.	2.9	17
44	p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clinical Cancer Research, 2018, 24, 3046-3052.	3.2	8
45	Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?â€”Reply. JAMA Oncology, 2018, 4, 423.	3.4	0
46	Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2018, 36, 136-143.	0.8	206
47	Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. JAMA Oncology, 2018, 4, 1199.	3.4	139
48	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.	1.9	33
49	Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer, 2018, 18, 504.	1.1	56
50	Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. PLoS ONE, 2018, 13, e0193048.	1.1	17
51	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. Journal of Clinical Oncology, 2018, 36, 3014-3014.	0.8	36
52	Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiation Research, 2017, 187, 186.	0.7	13
53	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. JAMA Oncology, 2017, 3, 793.	3.4	74
54	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 487-494.	0.9	16

#	Article	IF	Citations
55	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naÃ¯ve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. European Urology Focus, 2017, 3, 606-614.	1.6	18
56	Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib. JAMA Oncology, 2017, 3, 602.	3.4	141
57	SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour. British Journal of Cancer, 2017, 116, 1195-1202.	2.9	13
58	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	3.2	64
59	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer, 2017, 117, 1278-1285.	2.9	33
60	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research, 2017, 77, 5652-5663.	0.4	90
61	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyperÂ®. Breast Cancer Research, 2017, 19, 55.	2.2	29
62	Escalating and de-escalating treatment in HER2-positive early breast cancer. Cancer Treatment Reviews, 2017, 52, 1-11.	3.4	24
63	Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort. Cancer Research, 2017, 77, 134-141.	0.4	7
64	L-type calcium channels regulate filopodia stability and cancer cell invasion downstream of integrin signalling. Nature Communications, 2016, 7, 13297.	5.8	141
65	Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Research and Treatment, 2016, 157, 437-446.	1.1	33
66	Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour â€“ Does it increase the risk for tumour cell seeding and recurrence?. European Journal of Cancer, 2016, 59, 128-133.	1.3	39
67	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	3.2	43
68	Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice. International Journal of Cancer, 2016, 139, 2270-2276.	2.3	0
69	Increased pancreatic cancer risk following radiotherapy for testicular cancer. British Journal of Cancer, 2016, 115, 901-908.	2.9	30
70	Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nature Communications, 2016, 7, 12237.	5.8	105
71	Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 404-410.	0.4	29
72	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Research, 2016, 76, 264-274.	0.4	21

#	Article	IF	Citations
73	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology, 2016, 34, 244-250.	0.8	174
74	Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta OncolÃ³gica, 2016, 55, 188-192.	0.8	55
75	Sunitinibâ€induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU International, 2016, 117, 110-117.	1.3	47
76	Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.. Journal of Clinical Oncology, 2016, 34, 1001-1001.	0.8	3
77	Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2016, 34, 156-156.	0.8	9
78	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0153745.	1.1	20
79	KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology, 2015, 33, 634-642.	0.8	139
80	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer and Tumors â‰¤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. Journal of Clinical Oncology, 2015, 33, 2600-2608.	0.8	91
81	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist, 2015, 20, 823-830.	1.9	26
82	Cancer in Young Adults With Ischemic Stroke. Stroke, 2015, 46, 1601-1606.	1.0	44
83	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 2015, 51, 852-860.	1.3	23
84	Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells. American Journal of Pathology, 2015, 185, 987-1000.	1.9	68
85	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Medicine, 2015, 13, 177.	2.3	45
86	Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrenceâ€”Not Accurate Enough?. JAMA Oncology, 2015, 1, 805.	3.4	1
87	Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Research, 2015, 17, 101.	2.2	291
88	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	5.1	108
89	Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. Radiotherapy and Oncology, 2015, 116, 233-238.	0.3	34
90	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. Journal of Clinical Oncology, 2015, 33, 516-516.	0.8	5

#	Article	IF	Citations
91	An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID).. Journal of Clinical Oncology, 2015, 33, 110-110.	0.8	7
92	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget, 2015, 6, 30306-30316.	0.8	14
93	Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 461-461.	0.8	0
94	ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer. PLoS ONE, 2014, 9, e102388.	1.1	5
95	Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta OncolÃ³gica, 2014, 53, 186-194.	0.8	22
96	Gastrointestinal Stromal Tumor: A Method for Optimizing the Timing of CT Scans in the Follow-up of Cancer Patients. Radiology, 2014, 271, 96-106.	3.6	15
97	Early Pregnancy Sex Steroids and Maternal Breast Cancer: A Nested Caseâ€“Control Study. Cancer Research, 2014, 74, 6958-6967.	0.4	15
98	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 2014, 120, 2325-2333.	2.0	65
99	Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Research, 2014, 16, 209.	2.2	407
100	Dual targeting of HER2 with lapatinib and trastuzumab. Lancet Oncology, The, 2014, 15, 1050-1052.	5.1	3
101	Voice Quality After Treatment of Early Vocal Cord Cancer: A Randomized Trial Comparing Laser Surgery With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 255-260.	0.4	133
102	Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica, 2014, 99, e193-e196.	1.7	37
103	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	0.8	1
104	Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors â‰¤ 2cm: A meta-analysis of the randomized trastuzumab trials.. Journal of Clinical Oncology, 2014, 32, 508-508.	0.8	5
105	Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.. Journal of Clinical Oncology, 2014, 32, 23-23.	0.8	2
106	Management of small gastrointestinal stromal tumours â€“ Authors' reply. Lancet, The, 2013, 382, 1701-1702.	6.3	6
107	Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America, 2013, 27, 889-904.	0.9	13
108	Duration of adjuvant trastuzumab: shorter beats longer. Lancet, The, 2013, 382, 1010-1011.	6.3	5

#	Article	IF	Citations
109	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 295-302.	6.3	1,144
110	Gastrointestinal stromal tumour. Lancet, The, 2013, 382, 973-983.	6.3	518
111	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. Journal of Clinical Oncology, 2013, 31, 10503-10503.	0.8	26
112	Stomach cancer risk following radiotherapy for testicular cancer.. Journal of Clinical Oncology, 2013, 31, 4536-4536.	0.8	9
113	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. Journal of Clinical Oncology, 2013, 31, 10551-10551.	0.8	1
114	Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology, 2012, 30, 11-18.	0.8	114
115	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncology, The, 2012, 13, 265-274.	5.1	790
116	Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial. International Journal of Radiation Oncology Biology Physics, 2012, 82, e67-e75.	0.4	192
117	Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour. Drugs, 2012, 72, 1953-1963.	4.9	17
118	Adjuvant treatment of GIST: patient selection and treatment strategies. Nature Reviews Clinical Oncology, 2012, 9, 351-358.	12.5	60
119	The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy. Annual Review of Medicine, 2012, 63, 247-258.	5.0	119
120	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. JAMA - Journal of the American Medical Association, 2012, 307, 1265.	3.8	832
121	Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.. Journal of Clinical Oncology, 2012, 30, 507-507.	0.8	10
122	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	0.8	2
123	LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigatorâ€™s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy.. Journal of Clinical Oncology, 2012, 30, TPS647-TPS647.	0.8	3
124	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	0.8	11
125	Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treatment Reviews, 2011, 37, 75-88.	3.4	108
126	HERA crosses over. Lancet Oncology, The, 2011, 12, 203-204.	5.1	1

#	Article	IF	Citations
127	Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiotherapy and Oncology, 2011, 99, 98-99.	0.3	44
128	Unusually young Merkel cell carcinoma patients are Merkel cell polyomavirus positive and frequently immunocompromised. European Journal of Plastic Surgery, 2010, 33, 349-353.	0.3	8
129	Reply to M. Isik et al. Journal of Clinical Oncology, 2010, 28, e335-e336.	0.8	0
130	Risk of Treatment-Related Stomach Cancer Among Hodgkin Lymphoma Survivors. Blood, 2010, 116, 2679-2679.	0.6	0
131	Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. Journal of Clinical Oncology, 2009, 27, 5685-5692.	0.8	406
132	Reply to P.A. LeppÃluoto. Journal of Clinical Oncology, 2009, 27, 3066-3067.	0.8	0
133	Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology, The, 2009, 10, 1145-1151.	5.1	65
134	Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology, 2008, 39, 1411-1419.	1.1	977
135	Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncology, The, 2008, 9, 304.	5.1	52
136	Second line therapies for the treatment of gastrointestinal stromal tumor. Current Opinion in Oncology, 2007, 19, 353-358.	1.1	21
137	Cardiac toxicity of sunitinib. Lancet, The, 2007, 370, 1978-1980.	6.3	31
138	Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 475-482.	0.4	125
139	Sunitinib for imatinib-resistant GIST. Lancet, The, 2006, 368, 1303-1304.	6.3	56
140	Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. New England Journal of Medicine, 2006, 354, 809-820.	13.9	1,317
141	Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2006, 24, 4764-4774.	0.8	746
142	Amplification of genes encoding KIT, PDGFRÎ± and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. Journal of Pathology, 2005, 207, 224-231.	2.1	140
143	Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta OncolÃ³gica, 2005, 44, 23-31.	0.8	27
144	Risk for Distant Recurrence of Breast Cancer Detected by Mammography Screening or Other Methods. JAMA - Journal of the American Medical Association, 2004, 292, 1064.	3.8	165

#	Article	IF	Citations
145	Title is missing!. Journal of Neuro-Oncology, 2003, 62, 123-134.	1.4	17
146	Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. Journal of Neuro-Oncology, 2003, 62, 123-134.	1.4	156
147	Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2003, 21, 4342-4349.	0.8	2,160
148	Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clinical Cancer Research, 2003, 9, 923-30.	3.2	160
149	Management of malignant gastrointestinal stromal tumours. Lancet Oncology, The, 2002, 3, 655-664.	5.1	503
150	Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Medizinische Klinik, 2002, 97 Suppl 1, 28-30.	0.5	8
151	Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Research, 2002, 62, 5210-7.	0.4	136
152	Endotoxins induce and interferonâ€Î± suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. FASEB Journal, 2001, 15, 1318-1320.	0.2	18
153	Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Annals of Medicine, 2001, 33, 451-455.	1.5	94
154	PPP2R1BGene in Chronic Lymphocytic Leukemias and Mantle Cell Lymphomas. Leukemia and Lymphoma, 2001, 41, 177-183.	0.6	16
155	Amplification of c-myc Oncogene by Chromogenic and Fluorescence In Situ Hybridization in Archival Breast Cancer Tissue Array Samples. Laboratory Investigation, 2001, 81, 1545-1551.	1.7	44
156	Amplification of c-myc by Fluorescence In Situ Hybridization in a Population-Based Breast Cancer Tissue Array. Modern Pathology, 2001, 14, 1030-1035.	2.9	40
157	Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor. New England Journal of Medicine, 2001, 344, 1052-1056.	13.9	1,926
158	Novel cancer therapies: more efficacy, less toxicity and improved organ preservation. Annals of Medicine, 2000, 32, 31-33.	1.5	6
159	Serum CD44 Levels Preceding the Diagnosis of Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2000, 37, 585-592.	0.6	6
160	A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkinâ€™s Lymphoma. Blood, 1999, 94, 3334-3339.	0.6	102
161	BCL2 Overexpression in Diffuse Large B-Cell Lymphoma. Leukemia and Lymphoma, 1999, 34, 45-52.	0.6	38
162	Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma. British Journal of Haematology, 1999, 104, 665-671.	1.2	41

#	Article	IF	Citations
163	Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Research and Treatment, 1999, 53, 161-166.	1.1	99
164	Cytochrome P450?inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clinical Pharmacology and Therapeutics, 1999, 66, 589-593.	2.3	50
165	Late mortality from pT1N0M0 breast carcinoma. , 1999, 85, 2183-2189.		61
166	Serum CD44 in Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1999, 33, 433-440.	0.6	12
167	High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. , 1998, 79, 144-146.		232
168	Clinical significance of circulating CD44 in non-Hodgkin's lymphoma. , 1998, 79, 221-225.		8
169	Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. , 1998, 21, 298-307.		117
170	High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. , 1998, 79, 144.		2
171	High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. , 1998, 79, 144.		11
172	Stage I Non-Hodgkin's Lymphoma Treated with Doxorubicin-containing Chemotherapy with or without Radiotherapy. Acta OncolÃ³gica, 1997, 36, 619-624.	0.8	5
173	Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes and Cancer, 1997, 18, 286-291.	1.5	57
174	Treatment Results of Nasopharyngeal Cancer a nationwide survey from Finland. Acta OncolÃ³gica, 1996, 35, 697-702.	0.8	9
175	Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 214-218.	1.2	39
176	Special Section: Autologous Stem Cell Transplantations in Solid Tumours: Autologous Stem Cell Transplantation in Breast Cancer. Annals of Medicine, 1996, 28, 145-149.	1.5	1
177	Evidence for false aneuploid peaks in flow cytometric analysis of paraffin-embedded tissue. Cytometry, 1990, 11, 431-437.	1.8	49
178	Sarcoma and Gastrointestinal Stromal Tumors. , 0, , 227-258.		0